miR-301a expression: Diagnostic and prognostic marker for prostate cancer

Kolluru, Venkatesh; Chandrasekaran, Balaji; Tyagi, Ashish; Dervishi, Adnan; Ankem, Murali K.; Yan, Xin; Kong, Mei; Alatassi, Houda; Shaheen, Saad P.; Messer, Jamie; Edwards, Angelena; Haddad, Ahmed; Damodaran, Chendil

doi:10.1016/j.urolonc.2018.07.014

Cited by 20 publications

(18 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among differentially expressed miRNAs, most interestingly, the expression of miR-301 was upregulated in early-stage and CRPC progression, and this high expression of miR-301 was consistent in both serum and tumor tissue in prostate cancer patients compared to patients with benign prostate hyperplasia [22]. The CSmiR-Tar database identified erythroblastic oncogene B 2 (ERBB2) as a potential target gene of miR-301, across all cancer stages, with a binding site in the 5'UTR of ERBB2 which is structurally related to EGFR (Fig 5) [23].…”

Section: Discussionmentioning

confidence: 99%

Integrated analysis of miRNA landscape and cellular networking pathways in stage-specific prostate cancer

et al. 2019

View full text Add to dashboard Cite

Dysregulation of miRNAs has been demonstrated in several human malignancies including prostate cancer. Due to tissue limitation and variable disease progression, stage-specific miRNAs changes in prostate cancer is unknown. Using chip-based microarray, we investigated global miRNA expression in human prostate cancer LNCaP, PC3, DU145 and 22Rv1 cells representing early-stage, advanced-stage and castration resistant prostate cancer in comparison with normal prostate epithelial cells. A total of 292 miRNAs were differentially expressed with 125 upregulated and 167 downregulated. These miRNAs were involved in pathways including drug resistance drug-efflux, adipogenesis, epithelial-to-mesenchymal transition, bone metamorphosis, and Th1/Th2 signaling. Regulation of miRNAs were interlinked with upstream regulators such as Argonaut 2 (AGO2), Double-Stranded RNA-Specific Endoribonuclease (DICER1), Sjogren syndrome antigen B (SSB), neurofibromatosis 2 (NF2), and peroxisome proliferator activated receptor alpha (PPARA), activated during stage-specific disease progression. Candidate target genes and pathways dysregulated in stage-specific prostate cancer were identified using CS-miRTar database and confirmed in clinical specimens. Integrative network analysis suggested some genes targeted by miRNAs include miR-17, let7g, miR-146, miR-204, miR-205, miR-221, miR-301 and miR-520 having a major effect on their dysregulation in prostate cancer. MiRNA-microarray analysis further identified miR-130a, miR-181, miR-328, miR146 and miR-200 as a panel of novel miRNAs associated with drug resistance drug-efflux and epithelial-to-mesenchymal transition in prostate cancer. Our findings provide evidence on miRNA dysregulation and its association with key functional components in stage-specific prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Integrated analysis of miRNA landscape and cellular networking pathways in stage-specific prostate cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…miRNAs have been implicated as potential biomarkers in PCa as well as other cancer types and have been identified for their therapeutic potential [39]. An inverse relationship between expression of the RUNX family and their targeting miRNAs is also observed in patients [27]. miR-301a is highly expressed in serum and tissues of patients with Gleason 6 or 7 prostate adenocarcinoma compared to patients with BPH, whereas RUNX3, which is targeted by miR-301a, is absent in these tissue samples [27].…”

Section: Accepted Articlementioning

confidence: 99%

Role of the runt‐related transcription factor (RUNX) family in prostate cancer

et al. 2021

View full text Add to dashboard Cite

Prostate cancer (PCa) is a very complex disease that is a major cause of death in men worldwide. Currently, PCa dependence on the androgen receptor (AR) has resulted in use of AR antagonists and anti-androgen therapies that reduce endogenous steroid hormone production. However, within two to three years of receiving first line androgen deprivation therapy, the majority of patients diagnosed with PCa progress to castration resistant prostate cancer (CRPC). There is an urgent need for therapies that are more durable than antagonism of the AR axis. Studies of Runt-related transcription factors (RUNX) and their heterodimerization partner, Core-Binding Factor Subunit b (CBFβ), are revealing that the RUNX family are drivers of CRPC. In this review, we describe what is presently understood about RUNX members in PCa, including what regulates and is regulated by RUNX proteins, and the role of RUNX proteins in the tumor microenvironment and AR signaling. We discuss the implications for therapeutically targeting RUNX, the potential for RUNX as PCa biomarkers, and the current pressing questions in the field.

show abstract

“…Also miR-301a was found to be a valuable diagnostic and prognostic biomarker for prostate cancer disease. The study performed on 28 prostate cancer patients and 13 controls as well as 40 radical prostatectomy cases indicate the possible correlation between miR-301a detected in serum and Gleason score [ 162 ].…”

Section: Discussionmentioning

confidence: 99%

Systematic review and meta-analysis of the prognostic significance of microRNAs related to metastatic and EMT process among prostate cancer patients

et al. 2021

View full text Add to dashboard Cite

The ability of tumor cells to spread from their origin place and form secondary tumor foci is determined by the epithelial–mesenchymal transition process. In epithelial tumors such as prostate cancer (PCa), the loss of intercellular interactions can be observed as a change in expression of polarity proteins. Epithelial cells acquire ability to migrate, what leads to the formation of distal metastases. In recent years, the interest in miRNA molecules as potential future treatment options has increased. In tumor microenvironment, miRNAs have the ability to regulate signal transduction pathways, where they can act as suppressors or oncogenes. MiRNAs are secreted by cancer cells, and the changes in their expression levels are closely related to a cancer progression, including epithelial–mesenchymal transition. These molecules offer new diagnostic and therapeutic possibilities. Therapeutics which make use of synthesized RNA fragments and mimic or block miRNAs affected in PCa, may lead to inhibition of tumor progression and even disease re-emission. Based on appropriate qualification criteria, we conducted a selection process to identify scientific articles describing miRNAs and their relation to epithelial–mesenchymal transition in PCa patients. The studies were published in English on Pubmed, Scopus and the Web of Science before August 08, 2019. Hazard ratios (HRs) and 95% confidence intervals (CI) as well as total Gleason score were used to assess the concordance between miRNAs and presence of metastases. A total of 13 studies were included in our meta-analysis, representing 1608 PCa patients and 15 miRNA molecules. Our study clarifies a relationship between the clinicopathological features of PCa and the aberrant expression of several miRNA as well as the complex mechanism of miRNA molecules involvement in the induction and promotion of the metastatic mechanism in PCa.

show abstract

miR-301a expression: Diagnostic and prognostic marker for prostate cancer

Cited by 20 publications

References 39 publications

Integrated analysis of miRNA landscape and cellular networking pathways in stage-specific prostate cancer

Integrated analysis of miRNA landscape and cellular networking pathways in stage-specific prostate cancer

Role of the runt‐related transcription factor (RUNX) family in prostate cancer

Systematic review and meta-analysis of the prognostic significance of microRNAs related to metastatic and EMT process among prostate cancer patients

Contact Info

Product

Resources

About